Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Q4 2022 Earnings Call Transcript

Rami Katkhuda: Got it. And then I guess, are there any other key learnings from previous trials with iscalimab and belatacept that influences the design or expectations for BESTOW?

Steven Perrin: So BESTOW the protocol is already being €“ been approved. We have an approved protocol that we’re executing on in multiple €“ that we would plan on executing in multiple countries, but approval already here in the U.S. as you know. And that design was based on primarily at the time a wealth of data on the belatacept studies. That’s where most €“ that was probably the largest trials where data was available since tacrolimus was approved over 30 years ago. So much of the analysis was based on all of the data available from the belatacept studies.

David-Alexandre Gros: And some of the learnings from looking at those trials include the potential benefit of using ATG in combination with the costimulatory blocker, like an anti-CD40 ligand and hence our use of ATG for induction. And then another learning is the importance in keeping the root of administration the same. And as such, we are going to continue developing an IV solution here.

Steven Perrin: And I think one other learning as we’ve mentioned and it’s our primary endpoint is the ability to utilize eGFR as an indicator of kidney function. That was very exciting data that was part of the belatacept studies.

Rami Katkhuda: Got it. Thank you guys again.

Operator: At this time, I am showing no further questioners in the queue. And this does conclude our question-and-answer session. I would now like to turn the conference back over to DA Gros for any closing remarks.

David-Alexandre Gros: Thank you for your assistance operator, and thank you all for joining us on today’s call. Have a great afternoon and evening.

Operator: The conference has now concluded. Thank you for attending today’s presentation and you may now disconnect.